LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that in the matter of scheme of amalgamation of Lincoln Parenteral Limited ('Transferor Company') with Lincoln Pharmaceuticals Limited ('Transferee Company') and their respective Shareholders and Creditors ('Scheme'), Hon'ble National Company Law Tribunal, Ahmedabad Bench in its order dated February 09, 2021 have directed the Company to publish newspaper publication and final hearing on said matter shall be appear on March 31, 2021. LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish Rajanibhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
we enclosed herewith the copies of published newspaper advertisement with respect to the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months Ended December 31, 2020. The said advertisement was published in the following newspapers: 1.The Economic Times, Ahmedabad Edition - In English; 2. Jay Hind, Ahmedabad Edition - In Gujarati. Lincoln Pharma Q3 net up 31%
Pharma player, Lincoln Pharmaceuticals Limited posted standalone net profit at 13 crore for the quarter ended December 2020 as against 10 crore in t LINCOLN PHARMACEUTICALS LTD. - 531633 - Financial Result For The Quarter Ended December 31, 2020
We would like to inform that the Board of Directors of the Company at their meeting held today i.e. Tuesday, February 02, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter and nine months ended on December 31, 2020. We also enclose herewith financial highlights of the Company for the aforesaid quarter. LINCOLN PHARMACEUTICALS LTD. - 531633 - Outcome Of Board Meeting
We would like to inform that the Board of Directors of the Company at their meeting held today i.e. Tuesday, February 02, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter and nine months ended on December 31, 2020. We also enclose herewith financial highlights of the Company for the aforesaid quarter. LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) for the Quarter Ended December 31, 2020. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Inter-Alia To Consider And Approve The Un-Audited Financial Results For The Quarter And Nine-Months Ended On December 31, 2020
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2021 ,inter alia, to consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine-months ended on December 31, 2020 along with any other business, if any.